**Recent Advances in Replication and Infection of Human Parvovirus B19**

**Safder S. Ganaie and Jianming Qiu**

*Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, KS, United States*

Parvovirus B19 (B19V) is pathogenic to humans and causes bone marrow failure diseases and various other inflammatory disorders. B19V infection exhibits high tropism for human erythroid progenitor cells (EPCs) in the bone marrow and fetal liver. The exclusive restriction of B19V replication to erythroid lineage cells is partly due to the expression of receptor and co-receptor(s) on the cell surface of human EPCs and partly depends on the intracellular factors essential for virus replication. We first summarize the latest developments in the viral entry process and the host cellular factors or pathways critical for B19V replication. We discuss the role of hypoxia, erythropoietin signaling and STAT5 activation in the virus replication. The B19V infection-induced DNA damage response (DDR) and cell cycle arrest at late S-phase are two key events that promote B19V replication. Lately, the virus infection causes G2 arrest, followed by the extensive cell death of EPCs that leads to anemia. We provide the current understanding of how B19V exploits the cellular resources and manipulate pathways for efficient virus replication. B19V encodes a single precursor mRNA (pre-mRNA), which undergoes alternate splicing and alternative polyadenylation to generate at least 12 different species of mRNA transcripts. The post-transcriptional processing of B19V pre-mRNA is tightly regulated through cis-acting elements and trans-acting factors flanking the splice donor or acceptor sites. Overall, in this review, we focus on the recent advances in the molecular virology and pathogenesis of B19V infection.

**Keywords:** parvovirus B19, human, erythroid precursor cells, infection, DNA replication, RNA processing

**INTRODUCTION**

Parvovirus B19 (B19V) is a small, non-enveloped virus that has a diameter of approximately 23–26 nm and contains a linear single-stranded DNA genome of 5.6 kb, flanked by two identical terminal hairpin structures (Figure 1A) (Qiu et al., 2017). B19V belongs to *Erythroparvovirus* of the *Parvoviridae* family (Cotmore et al., 2014). The name B19 was coined after the sample number containing the virus; panel B and no.19, during the screening of hepatitis B virus (Cossart et al., 1975). B19V infection causes several diseases in humans, including like fifth disease in children (Brass et al., 1982), transient aplastic crisis (Chorba et al., 1986), non-immune hydrops fetalis in pregnant women (Parilla et al., 1997), persistent anemia in immunocompromised patients, arthropathy (Hosszu and Sallai, 1997), cardiomyopathy (Simpson et al., 2016) and inflammation of various other tissues (Adamson-Small et al., 2014; Qiu et al., 2017).
In this review, we focus on recent advances in B19V tropism, viral DNA replication and viral transcription. Importantly, we will focus on four key factors involved in B19V replication that are: (a) erythropoietin (EPO) signaling; (b) hypoxia; (c) DNA damage response (DDR); and (d) late S-phase arrest. We also summarize the new advancements in B19V pre-mRNA processing and its regulation. We also discuss host factors STAT5 (Signal Transducer and Activator of Transcription-5) and RBM38 (RNA-Binding Motif protein-38), which regulate virus replication and mRNA processing, respectively. Lastly, we discuss the underlying mechanism of NS1 induced cell cycle arrest, B19V pathogenesis, and the future directions in the development of therapeutics for B19V infection.

VIRAL ENTRY AND DETERMINANTS OF VIRAL TROPISM

Productive infection of B19V is restricted to human erythroid progenitor cells, particularly, during the stages of burst forming unit-erythroid (BFU-E) to colony forming unit-erythroid (CFU-E) (Young et al., 1984a; Srivastava and Lu, 1988). B19V infects ex vivo expanded EPCs from human bone marrow (Young et al., 1984a; Ozawa et al., 1986; Srivastava and Lu, 1988), peripheral and umbilical blood (Serke et al., 1991; Schwarz et al., 1992; Sosa et al., 1992; Srivastava et al., 1992) and the fetal liver (Yaegashi et al., 1989; Morey and Fleming, 1992). In addition to expanded primary EPCs, various other cell lines have been used.
for B19V infection, including MB-02, UT7/Epo and UT7/Epo-S1 (megakaryoblastoid cell lines) (Shimomura et al., 1992; Munshi et al., 1993; Morita et al., 2001) and JK-1, KU812-Ep6 (erythroid leukemia cell lines) (Takahashi et al., 1993; Miyagawa et al., 1999). For efficient B19V replication, erythropoietin and hypoxia play a critical role under in vitro conditions (Chen et al., 2010a, 2011). B19V also infects endothelial cells of various tissues, but the infection is largely non-productive (Adamson-Small et al., 2014). In addition, U937 cells, circulating angiogenic cells (CACs) and CD34+ endothelial progenitor cells from bone marrow have also been reported to be susceptible to B19V infection (Munakata et al., 2006; Schmidt-Lucke et al., 2010, 2015). All these cells either express viral receptor/co-receptors or use an antibody dependent route via c1q receptor for viral entry (von Kietzell et al., 2014).

The primary receptor for B19V is globoside or P antigen (Figure 2) (Brown et al., 1993). However, all P antigen expressing cells are not permissive to B19V (Weigel-Kelley et al., 2001). Various other co-receptors like Ku80 (Munakata et al., 2005), integrin α5β1 (Weigel-Kelley et al., 2003) and antibody-mediated B19V entry routes (von Kietzell et al., 2014) are presumed to be involved in B19V entry. Importantly, the B19V capsid binds its primary receptor, P antigen and undergoes a conformational change, exposing VP1u, a unique (273 aa) N-terminus of the VP1 capsid protein (Figure 2) (Ros et al., 2006; Bonsch et al., 2008, 2010). Since Ku80 and α5β1 integrin haven’t been shown to interact with VP1u, it has been hypothesized that VP1u interacts with some unknown co-receptor for subsequent internalization. Further, the N-terminal 100 amino acids of VP1u are required for internalization, which implies that the PLA2 (phospholipase A2) activity of VP1u is not essential for viral entry (Leisi et al., 2013). Interestingly, the VP1u region (without capsid) is efficiently internalized by B19V-permissive cells (Leisi et al., 2016a,b), which suggests that primary interaction of B19V with P antigen is required only for externalization of VP1u. Mature RBCs also express P antigen and hence show primary attachment to B19V, but the virus is not internalized (Bonsch et al., 2008). It is presumed that this primary interaction may be responsible for systemic dissemination of the virus. Similar to other paroviruses, B19V uses the endocytic pathway but escapes lysosomal degradation to enter the nucleus for subsequent replication, transcription and packaging (Figure 2) (Harbison et al., 2008; Quattrocchi et al., 2012). In conclusion, the B19V

![Figure 2](image-url.com)
first interaction with the globoside leads to the externalization of VP1u, which then interacts with some unknown co-receptor for internalization of the virus.

**GENE EXPRESSION, SPLICING, AND ITS REGULATION**

Upon entry of the virus into the nucleus, the B19V ssDNA genome is converted to double-stranded replicative form (dsRF), which acts a template for both DNA replication and transcription (Figure 2) (Cotmore and Tattersall, 2014). The dsRF viral DNA has a unique but single promoter at map unit 6 (P6) that expresses a single precursor mRNA (pre-mRNA) (Figure 1B) (Blundell et al., 1987; Doerig et al., 1987). The P6 promoter has an upstream enhancer region and NS1 binding elements that bind transcription factors (e.g., CREBP, GATA, Oct1 etc.) and NS1 protein, respectively, for promoter transactivation (Blundell and Astell, 1989; Liu et al., 1991; Momoeda et al., 1994a; Raab et al., 2001). B19V pre-mRNA undergoes alternative splicing and polyadenylation to express at least 12 mature mRNA transcripts that encode two structural (VP1 and VP2) and three non-structural (NS1, 7.5 and 11-kDa) proteins (Ozawa et al., 1987; Beard et al., 1989; Yoto et al., 2006). The pre-mRNA contains two splice donor sites (D1 and D2) and four acceptor sites (A1-1, A1-2, A2-1, and A2-2) (Figure 1B) (Qiu et al., 2017). In addition, it harbors two proximal [p(A)p]1/2 and a distal [p(A)p] polyadenylation sites (Figure 1B) (Qiu et al., 2017). Unspliced mRNA transcripts (R1 and R1′) that polyadenylate at (pA)p encode the NS1 protein while those spliced at A1-1 (R2 and R2′) and use (pA)p sites encode the 7.5-kDa protein (Figure 1B). The mRNA transcripts polyadenylated at (pA)d and where 1st intron (R4 and R5), 1st and 2nd (R6 and R7), and 1st, 2nd, and 3rd introns (R8 and R9) are spliced out encode the VP1, VP2, and 11-kDa proteins, respectively (Figure 1B) (Luo and Astell, 1993; St Amand and Astell, 1993; Yoto et al., 2006). Whether other mRNAs (R3 and R3′) encode a protein or play any role during virus infection is unknown.

While the B19V mRNAs are splice products from a single pre-mRNA, the expression levels of the different encoded proteins varies considerably (Guän et al., 2011b). Therefore, the virus must employ different strategies to regulate the level of gene expression. In the absence of viral DNA replication, most of the mRNA transcripts polyadenylate at (pA)p leading to the expression of NS1 and 7.5-kDa proteins in both B19V-permissive or non-permissive cells (Figure 1B) (Liu et al., 1992). Viral DNA replication facilitates the read-through of (pA)p and overcomes the blockade to express mRNAs that polyadenylate at (pA)d encoding for the VP1, VP2 and 11-kDa proteins (Guan et al., 2008). Thus, the early and late phases of virus infection are dominated by NS1-encoding and VP1-11-kDa-encoding mRNAs, respectively (Bua et al., 2016). An alternative model for virus infection was also proposed suggesting that B19V genome be considered as single, two state replicative and transcription unit, where the increase in viral RNA correlates with viral DNA levels (Bonvici et al., 2006). Next, the central exon or exon 2 (spanning A1-1/2 to D2) harbors serine arginine (SR) protein binding GAA motifs, and the GAA motif between A1-1 and A1-2, constitutes exon splicing enhancer 1 (ESE1), which defines exon-2 and facilitates splicing at A1-1. The 5′ end of exon 2 promotes splicing at A1-2 and serves as exon splicing enhancer 2 (ESE2) (Guan et al., 2011a). Splicing at second donor site (D2) is critical for the expression of capsid proteins and 11-kDa encoding mRNAs, and also competes with polyadenylation at (pA)p (Guan et al., 2011b). Binding of U1 snRNA to D2 splice donor site inhibits polyadenylation at (pA)p (Guan et al., 2011a). D2 is a weak splice donor site and requires two cis-acting elements: exon splicing enhancer 3 (ESE3) and intron splicing enhancer 2 (ISE2) for its efficient splicing (Guan et al., 2011a). Hence, the interplay of cis-acting elements and trans-acting factors determine the splicing efficiency of different splice sites to regulate the expression of different mRNA species. While looking for the trans-acting factors that bind ISE2, we demonstrate that RNA binding protein-RBM38, expressed in the middle stages of erythropoiesis, promotes the expression of 11-kDa protein (Ganaie et al., 2018). Specifically, RBM38 binds ISE2 and promotes splicing of third intron (D2 to A2-2), that results in the production of 11-kDa encoding mRNAs. Therefore, RBM38 is one of the essential trans-acting factors that regulates the expression of 11-kDa protein (Ganaie et al., 2018). In conclusion, B19V efficiently uses the alternative splicing and alternative polyadenylation processes to ensure the expression of the viral proteins at a given ratio. However, such tight regulation is dependent on the cis-acting elements and the trans-acting factors flanking the splice donor/acceptor sites.

**VIRAL PROTEINS AND THEIR FUNCTIONS**

B19V expresses three non-structural (NS1, 11- and 7.5-kDa) and two structural proteins (VP1 and VP2).

**Non-structural Proteins**

**Non-structural Protein 1 (NS1)**

NS1 is 671 amino acid long protein that has a MW of ~78 kDa. NS1 contains two nuclear localization signals; KKPR (177–179) and KKCGKK (316–321) (Figure 3) and is found predominantly in the nucleus of infected cells (Cotmore et al., 1986; Ozawa and Young, 1987; Ozawa et al., 1987; Wan et al., 2010). NS1 contains a DNA binding and endonuclease domain at the N-terminus (Tewary et al., 2014), an ATPase and NTP-binding domains in the central region (Momoeda et al., 1994b) and a transactivation domain at its C-terminus (Lou et al., 2012) (Figure 3). NS1 is critical for virus DNA replication (Zhi et al., 2006), and binds NSBEs (NS1 binding elements) of the minimum origin of replication of B19V dsRF DNA (Figure 4) (Tewary et al., 2014). Upon NS1 binding to NSBEs, it presumably opens up the dsRF DNA and nicks the ssDNA substrate at trs (terminal resolution site) (Figure 2) (Sanchez et al., 2016). With the assistance of Sp1/Sp3, NS1 binds P6 promoter for its transactivation (Gareus et al., 1998; Raab et al., 2002). NS1 induces apoptosis via NTP-binding motif (328–335 amino acid) (Momoeda et al., 1994b; Moffatt et al., 1998; Poole et al., 2006), a DNA damage response (Lou et al., 2011; Lou et al., 2012) and cell cycle arrest (Morita et al., 2003; Wan et al., 2010; Luo et al., 2013; Xu et al., 2017).
We demonstrate that the 11-kDa protein is expressed at high levels during B19V infection (Figure 5). Upon microarray analysis of the dynamic transcriptome of B19V infected EPCs, we recently found that DNA metabolism, DNA replication, DNA repair, DNA damage response, cell cycle and cell cycle arrest pathways are significantly altered upon virus infection (Zou et al., 2017). Broadly, B19V replication is regulated by the following factors:

**EPO-Signaling**

In response to low oxygen tension, human kidney interstitial fibroblasts secrete EPO, a glycoprotein cytokine that promotes the differentiation and development of erythroid progenitors that results in the production of mature RBCs (Testa, 2004). During erythropoiesis, pluripotent hematopoietic stem cells (HSCs, CD34+) are differentiated into enucleated erythrocytes, encompassing the following stages – BFU-Es, CFU-Es, normoblasts, erythroblasts, reticulocytes and finally the mature erythrocytes (Ogawa, 1993; Testa, 2004). The earlier stages of differentiation are EPO-independent (Ogawa, 1993), and rely on factors like, stem cell factor (SCF) (Dai et al., 1991; Papayannopoulou et al., 1993), IL-6 (Sui et al., 1996), and IL-3 (Papayannopoulou et al., 1993). However, the late stage differentiation process requires EPO (Kouri and Bondurant, 1992; Ogawa, 1993). The exclusive tropism of B19V for erythroid progenitor cells partly depends on the expression of receptor and co-receptors on the cell surface and partly on the essential host. The 11-kDa protein is expressed at high levels during B19V infection (Figure 5). Upon microarray analysis of the dynamic transcriptome of B19V infected EPCs, we recently found that DNA metabolism, DNA replication, DNA repair, DNA damage response, cell cycle and cell cycle arrest pathways are significantly altered upon virus infection (Zou et al., 2017). Broadly, B19V replication is regulated by the following factors:

**EPO-Signaling**

In response to low oxygen tension, human kidney interstitial fibroblasts secrete EPO, a glycoprotein cytokine that promotes the differentiation and development of erythroid progenitors that results in the production of mature RBCs (Testa, 2004). During erythropoiesis, pluripotent hematopoietic stem cells (HSCs, CD34+) are differentiated into enucleated erythrocytes, encompassing the following stages – BFU-Es, CFU-Es, normoblasts, erythroblasts, reticulocytes and finally the mature erythrocytes (Ogawa, 1993; Testa, 2004). The earlier stages of differentiation are EPO-independent (Ogawa, 1993), and rely on factors like, stem cell factor (SCF) (Dai et al., 1991; Papayannopoulou et al., 1993), IL-6 (Sui et al., 1996), and IL-3 (Papayannopoulou et al., 1993). However, the late stage differentiation process requires EPO (Kouri and Bondurant, 1992; Ogawa, 1993). The exclusive tropism of B19V for erythroid progenitor cells partly depends on the expression of receptor and co-receptors on the cell surface and partly on the essential host.
cellular factors for efficient virus replication. Erythroid lineage cells depend on EPO for survival (Grebien et al., 2008), but B19V also needs EPO for its replication (Chen et al., 2010a). BFU-Es and CFU-Es, the late stage erythroblasts, are highly susceptible to B19V infection (Takahashi et al., 1990). B19V-semi permissive cell lines (e.g., UT7/Epo-S1) depend on EPO for cell proliferation and survival. Interestingly, B19V-permissivity of these cell lines strictly depends on EPO (Figure 2) (Takahashi et al., 1990). CD36+ EPCs differentiated from CD34+ in the absence of EPO are not permissive to B19V infection and B19V genome replicates only in the presence of EPO and requires phosphorylated Janus kinase 2 (JAK2) (Chen et al., 2010a). EPO binds EPO-receptor and activates ERK, Phosphoinositide 3-kinase (PI3K) and JAK2-STAT5 pathways (Figure 2) (Lodish et al., 2009). JAK2-STAT5 pathway is essential for B19V replication while the ERK pathway negatively regulates B19V replication and PI3K is dispensable for virus replication (Chen et al., 2011). Although EPO signaling activates the ERK pathway, B19V inhibits the ERK pathway presumably through its 11-kDa protein (Fan et al., 2001; Chen et al., 2011). Therefore, B19V fine tunes the EPO-signaling that favors efficient virus replication. In order to understand the underlying mechanism of STAT5 dependent B19V replication, we demonstrate that STAT5 phosphorylation is critical for B19V DNA replication (Ganaie et al., 2017). The viral Ori harbors a STAT5 binding site (Figure 4) and phosphorylated STAT5 binds viral origins both in-vivo as well as in-vitro (Ganaie et al., 2017). The mutation of STAT5 binding site within viral origins completely abolishes viral DNA replication (Ganaie et al., 2017). Furthermore, STAT5 interacts with the MCM complex and the disruption of STAT5-Ori complex leads to decrease in virus DNA replication and the abundance of MCM complex decreases significantly at the viral Ori (Ganaie et al., 2017). Therefore, in our proposed model, B19V utilizes the STAT5 interaction with viral Ori to recruit the MCM complex for initiation of viral DNA replication (Ganaie et al., 2017).

Hypoxia
During the propagation of B19V in ex-vivo expanded CD36+ EPCs, progeny virion production is not as efficient as under natural conditions in human bone marrow on B19V infection of EPCs. The viremia in B19V infected patients goes up to $10^{13}$ genomic copies per ml of plasma (Wong and Brown, 2006; Takano and Yamada, 2007), which indicates the requirement of other factors in determining the production of virions. Oxygen tension is low in bone marrow (Rogers et al., 2008) and lower oxygen pressure favors erythroid cell development in culture (Koller et al., 1992). Interestingly, B19V infected human EPCs at hypoxia (1% O$_2$) enhances viral gene expression, viral replication, and virus production. Hypoxia augmentation of B19V replication is independent...
of the PHD/HIFα pathway. Hypoxia also enables the B19V-infected pluripotent erythroid cells (KU812F) to yield high progeny virions (Caillet-Fauquet et al., 2004). Increase in the productive B19V infection under hypoxic conditions wasn’t due to increase in the B19V entry or intracellular trafficking of the virus. Also, HIF-1 was shown not to play any role in hypoxia-induced enhancement in B19V infectivity (Chen et al., 2011). However, hypoxia regulates the EPO/EPO-receptor signaling pathway by upregulating STAT5 and downregulating MEK activation, thereby enhancing B19V DNA replication in both B19V-infected EPCs and M20 (infected clone)-transfected UT7/Epo-S1 cells (Chen et al., 2011). We strongly believe that upregulation of STAT5 and downregulation of MEK/ERK signaling during hypoxia promotes virus replication. The B19V infectious clone grows rapidly (~80 times) in UT7/Epo-S1 cells under hypoxia (Chen et al., 2011). The culture of EPCs or UT7/Epo-S1 cells under hypoxia for B19V propagation is currently the best culture system in use. The efficient replication of M20 infectious clone and the subsequent production of infectious virions holds promise to study B19V replication and the underlying mechanism(s) of replication. Also, mutagenesis of B19V molecular clone M20 could help to understand the role of individual viral proteins and the specific protein domains in virus replication.

Late S Phase Cell Cycle

B19V DNA replication is dependent on host cellular DNA replication, since the virus doesn’t encode a viral DNA polymerase (Luo and Qiu, 2015). B19V induces cell cycle arrest in both virus-infected CD34+ EPCs and UT7/Epo-S1 or M20 transfected UT7/Epo-S1 cells at G2/M (Morita et al., 2001; Luo et al., 2013). Virus infected UT7/Epo-S1-arrested cells display 4N DNA content and (5′-bromo-2-deoxy-uridine) BrdU-pulse labeling for de novo DNA synthesis along with DAPI staining indicates that the cells are precisely in late-S phase (Luo et al., 2013). Upon B19V infection of UT7/Epo-S1, cyclin A, cyclin B1 and phosphorylated cell division cycle 2 (CDC2) were shown to accumulate and CDC2-cyclin B1 complex displayed enhanced kinase activity (Morita et al., 2001). The sequestration of cyclin B1 to the cytoplasm in B19V-infected cells indicates that B19V somehow prevents its import to nucleus, thus results into cell cycle arrest at G2 phase (Morita et al., 2001). NS1 alone has been shown to induce a true G2/M cell cycle arrest, doesn’t show BrdU incorporation but displays 4N DNA content (Luo et al., 2013), and de-regulation of E2F family transcription factors have been implicated for such arrest (Wan et al., 2010).

While B19V induces DDR that promotes virus replication, virus-induced DDR is not involved in cell cycle arrest at G2/M (Lou et al., 2012). Like other autonomous parvoviruses, B19V infection also induces arrest at S phase (Lou et al., 2011, 2013). Therefore, B19V induced late S phase arrest is possibly an outcome of replication-induced S phase arrest and NS1-induced G2/M arrest. Various S phase replication factors like polymerase delta (pol δ), proliferating cell nuclear antigen (PCNA), replication factor C-subunit 1 (RFC-1), the MCM complex except the DNA repair DNA polymerases are actively recruited to viral replication centers with pol δ and pol α essential for viral DNA replication (Luo et al., 2013; Zou et al., 2017). It is likely that like other paroviruses (Parris and Bates, 1976; Oleksiewicz and Alexandersen, 1997; Deleu et al., 1999), B19V exploits the cell cycle arrest at late S phase and uses S phase factors to for viral DNA replication. In addition, replication protein A-32 (RPA32) also colocalizes with viral replicating machinery. Although phosphorylated RPA32 forms also show colocalization, phosphorylation itself seems dispensable for virus replication (Zou et al., 2017), supporting the observation that B19V uses S phase for genome amplification.

DNA Damage Response (DDR)

DNA damage response (DDR) is a cellular defense mechanism to preserve genomic stability and integrity in response to double strand breaks (DSBs), single strand DNA breaks, or installed replication (Giccia and Elledge, 2010). There are three major kinases (mediators) responsible for signaling downstream DDR effects, including Ataxia telangiectasia mutated (ATM), Ataxia telangiectasia and Rad3 related (ATR), and DNA dependent protein kinase, catalytic subunit (DNA-PKcs). Apart from recognizing the damaged cellular DNA, DDR is also activated by various DNA viruses either to combat the infection by invoking innate immune response or to facilitate viral DNA replication (Luo and Qiu, 2015; Trigg and Ferguson, 2015). B19V infection induces a DDR by activating all the three PI3K kinases (ATR, ATM, and DNA-PKcs) (Luo et al., 2011). Phosphorylated ATM, ATR, DNA-PKcs and their downstream effectors (CHK1, CHK2, and Ku70/80) localize within the virus replication centers. Activated ATR and DNA-PKcs, but not ATM were found essential for B19V replication (Luo et al., 2011; Lou et al., 2012). Further, it was found that mere expression of the viral genes didn’t lead to the phosphorylation of RPA32 and γH2AX, a hallmark of DDR (Lou et al., 2012). Interestingly, NS1 itself phosphorylates ATR to induces cell cycle arrest, however, such activation of ATR doesn’t lead to phosphorylation of RPA32 and γH2AX (Xu et al., 2017). It was found that replicating, infectious clone-M20, but not a replication deficient M20 mutant, led to the induction of DDR (Lou et al., 2012), which implies that the replication process per se is responsible for inducing DDR.

In conclusion, Epo signaling and the virus-induced DDR and late S-phase arrest are essential for the efficient virus replication. Hypoxia stimulates virus replication through upregulation of the STAT5A. These findings have revealed the new mechanistic insights into B19V replication and also helped in the identification of novel targets for inhibiting B19V at the replication level. However, it remains to be seen that how virus infection-induced DDR promotes the efficient B19V replication in the erythroid cells?

VIRAL PATHOGENESIS

Productive Infection of B19V Induces Cell Cycle Arrest and Erythroid Cell Death

B19V infection induces cell cycle arrest at G2 phase (Morita et al., 2001). Upon further analyses of the cell cycle during the virus infection, it was found that the arrest at G2 phase has 4N DNA content but also incorporates BrdU, a thymidine analog,
suggested that the infected cells are in late S phase (Luo et al., 2013). During early infection, the cells are precisely at late S phase, however, at the late phase of infection most infected cells are found in G2 phase (Luo et al., 2013). Interestingly, the expression of NS1 induces a true G2 arrest where cells don’t incorporate BrdU but only exhibit 4N DNA content (Luo et al., 2013). There are many players responsible for inducing cell cycle arrest during B19V infection. During the B19V induced cell cycle arrest of UT7/Epo-S1 cells, it was observed that nuclear import of CDC2/cyclin B1 is prevented (Morita et al., 2001). NS1 itself causes a true G2 arrest by impinging the repressive E2F transcription factors (E2F4/E2F5) (Wan et al., 2010). A putative NS1 transactivation domain-2 (TAD2) was found responsible for NS1-induced G2 arrest (Lou et al., 2012). Recently, we explored the underlying mechanism of the NS1 induced cell cycle arrest in great detail (Xu et al., 2017). NS1-TAD2 domain transactivates several host genes that lead to the activation of ATR. Activated ATR phosphorylates cell division cycle 25C (CDC25C) at serine-216 through the activation of CHK1 (Xu et al., 2017). Phosphorylated CDC25C at S216 reduces its phosphatase activity and renders it complexed with 14-3-3 protein in the cytoplasm (Peng et al., 1998). As a result, inactive CDC25C is unable to dephosphorylate cyclin B1/CDK1 (pT14/Y15) complex to activate it. An active cyclin B1/CDK1 complex is essential for G2 to M transition (Dunphy et al., 1988). In NS1-expressing UT7/Epo-S1 cells, nuclear entry of cyclin B1/CDK1 complex is not hampered, rather the complex exhibits reduced kinase activity (Xu et al., 2017). Hence, B19V NS1 induces G2 arrest by activating the ATR-CDC25C-CDK1 pathway (Xu et al., 2017). NS1 activation of ATR doesn’t lead to the activation of γH2AX and RPA32, a hallmark of DDR (Lou et al., 2012; Xu et al., 2017). Moreover, DNA replication induced DDR and thereafter, activation of ATR leads to the arrest of cells at late S phase (Luo et al., 2013). It appears that NS1 or DNA replication mediated activation of ATR transduce signaling through different downstream pathways and results in cells arrested at different phases of cell cycle. The last factor implicated in B19V infection induced cell cycle arrest is the viral genome itself. A nucleotide sequence 5′-GGTTTTG T-3′ from the viral promoter region arrests BFU-E progenitor cells at S and G2/M phase (Guo et al., 2010). This promoter sequence is a CpG oligonucleotide-2006 analog that is a ligand of toll-like receptor 9 (TLR9). It appears that viral genomic replication initially stalls infected cells at late S phase and later with the help of NS1 arrests at G2/M, which eventually leads to cell death. B19V infection specifically targets BFU-E and CFU-E progenitor cells (Mortimer et al., 1983), disrupts erythropoiesis and results in the transient aplastic crisis (Young et al., 1984b). The virus-induced cell death is apoptotic in nature and involves caspase-3/6/8 activation (Moffatt et al., 1998; Sol et al., 1999). B19V NS1 activates the extrinsic apoptotic pathway involving the TNF-α pathway in CD34+ EPCs or UT7/Epo cells (Sol et al., 1999). The B19V encoded 11-kDa protein is also implicated in causing cell death through apoptosis, which involves caspase-10 (Chen et al., 2010b). It was found that 11-kDa is a more potent inducer of apoptosis than NS1 (Chen et al., 2010b).

Non-productive Infection of B19V Causes Inflammatory Diseases of Various Tissues

Virus infection is seen in non-erythroid cells as well. The virus uses an alternative entry route by complexing with antibody and entering through complement factor C1q and C1q receptor mediated endocytosis (von Kietzell et al., 2014). There is no clear evidence that B19V replicates or produces virions in any non-erythroid cell lineage, hence the infection is considered largely non-productive.

B19V predominantly infects endothelial cells of various tissues (e.g., aorta, umbilical vein, and pulmonary artery etc.) (von Kietzell et al., 2014). Other cell lines infected include U937 cells (Munakata et al., 2006), circularatory angiogenic cells (CACs) and CD34+ KDR+ endothelial progenitor cells (Schmidt-Lucke et al., 2010, 2015). B19V infection appears to be persistent and viral genes are silenced through methylation of CpG sites on the DNA (Bonvicini et al., 2012). Even after the infection is resolved, the viral DNA can be found in various tissues like spleen, liver, tonsils, testes and brain (Kerr, 2000; Adamson-Small et al., 2014).

Upon infection, the infected tissue evokes host-cellular response against the virus which culminates in a myriad of pathologies. B19V infection has been linked to several inflammatory diseases like cardiomyopathy (Simpson et al., 2016), rheumatoid arthritis (Simpson et al., 1984), hepatitis (Longo et al., 1998), vasculitis (Finkel et al., 1994), meningoencephalitis (Adamson-Small et al., 2014; Qiu et al., 2017). B19V infection or the expression of viral proteins can modulate the immune response. NS1 upregulates IFNAR1 and IL-2 (inflammatory response) and downregulates OAS1 and TYK2 (antiviral response) through the activation of STAT3/PIAS3 signaling pathway in human endothelial cells (HMEC-1) (Duechting et al., 2008). The increase in the expression of inflammatory molecules like NF-κB, IL-6 and COX2 correlated with expression of viral capsid proteins in the colon, thyroid and synoviocytes (Lu et al., 2006; Li et al., 2007; Wang et al., 2008; Polcz et al., 2013). Particularly, in synoviocytes, VP1u phospholipase A2 activity is implicated in the production of inflammatory response (Lu et al., 2006). NS1 induces apoptosis in hepatocytes through the activation of caspase-3 and caspase-9 (Poole et al., 2004, 2006).

In conclusion, the B19V productive infection causes cell death of the erythroid progenitors and the non-productive infection of non-erythroid tissues evokes inflammatory responses that leads to various pathologies. However, with the exception of the placental endothelium (Pasquinelli et al., 2009), no other non-erythroid cell type supports B19V multiplication.

CONCLUSION AND FUTURE DIRECTIONS

It has been reported that almost 40–60% of the world’s population is infected with parvovirus B19 (Nunoue et al., 1985). However, such persistent infection is at sub-immunogenic levels, as viral load is kept under control by our immune system (Anderson et al., 1986; Kurtzman et al., 1989), particularly by neutralizing antibodies against B19V VP1u region (Anderson et al., 1995). During times when patients are under immunosuppression or
during infection with other pathogens, the viral load increases, causing extensive cell death of erythroid progenitor cells and leads to various inflammatory diseases as described above (Heegaard and Brown, 2002; Qiu et al., 2017).

There is no specific treatment for B19V infection, except IVIG treatment (Watanabe and Kawashima, 2015) or blood transfusion (Soothill, 1990), so there is a need to develop antivirals for B19V infection. The new advancements in the field of B19V viral replication have identified various critical steps during the process of virus replication. One such important step is NS1 binding to the viral origin and subsequent nicking of B19V DNA at trs (Tewary et al., 2014). Recently, an in-vitro nicking assay for NS1 was developed (Sanchez et al., 2016), which could be utilized to screen for inhibitors of NS1 nicking. Furthermore, since the VP1u region is essential for viral entry and therefore, the peptide analogs of VP1u (1-100) (Leisi et al., 2013) or neutralizing monoclonal antibodies (Gigler et al., 1999) against VP1u can be employed to check B19V entry. We have demonstrated that STAT5 phosphorylation is essential for B19V DNA replication (Ganaie et al., 2017). Pimozone, a STAT5 inhibitor and an FDA approved drug abolishes virus replication in CD36+/ EPCs (Ganaie et al., 2017). However the levels used in patients are too low to inhibit B19V. Therefore, derivatives of pimozone could be explored as potential drugs for B19V infection and for B19 related pathologies and included in prophylactic antivirals for transplant recipients. However, the development of new antivirals against B19V infection needs an animal model to validate any new treatment. Currently, simian parvovirus (SPV) infection of cynomolgus monkeys (O’Sullivan et al., 1994) is an alternative to screen anti-B19 antivirals in animal model system.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**FUNDING**

This study was supported in full by PHS grant R01 AI070723 from the National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**REFERENCES**

Adamson-Small, L. A., Ignatovich, I. V., Laemmerhirt, M. G., and Hobbs, J. A. (2014). Persistent parvovirus B19 infection in non-erythroid tissues: possible role in the inflammatory and disease process. *Virus Res.* 190, 8–16. doi: 10.1016/j.virusres.2014.06.017

Anderson, L. J., Tsou, C., Parker, R. A., Chorbha, T. L., Wulfh, H., Tattersall, P., et al. (1986). Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. *J. Clin. Microbiol.* 24, 522–526.

Anderson, S., Momoeda, M., Kawase, M., Kajigaya, S., and Young, N. S. (1995). Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. *Virology* 206, 626–632. doi: 10.1016/S0042-6822(95)80079-4

Beard, C., St Amand, J., and Astell, C. R. (1989). Transient expression of B19 parvovirus gene products in COS-7 cells transfected with B19 SV40 hybrid vectors. *Virology* 172, 659–664. doi: 10.1016/0042-6822(89)90211-0

Blundell, M. C., and Astell, C. R. (1989). A GC-box motif upstream of the B19 parvovirus unique promoter is important for in vitro transcription. *J. Virol.* 63, 4814–4823.

Blundell, M. C., Beard, C., and Astell, C. R. (1987). In vitro identification of a B19 parvovirus promoter. *Virology* 157, 534–538. doi: 10.1016/0042-6822(87)90296-0

Bonsch, C., Kempf, C., and Ros, C. (2008). Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. *J. Virol.* 82, 11784–11791. doi: 10.1128/JVI.01399-08

Bonsch, C., Zuecher, C., Lieby, P., Kempf, C., and Ros, C. (2010). The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization. *J. Virol.* 84, 11737–11746. doi: 10.1128/JVI.01143-10

Bonvicini, F., Filippone, C., Delbarba, S., Manaresi, E., Zerbini, M., Musiani, M., et al. (2006). Parvovirus B19 genome as a single, two-state replicative and transcriptional unit. *Virology* 347, 447–454. doi: 10.1016/j.virology.2005.12.014

Bonvicini, F., Manaresi, E., Di Furio, F., De Falco, L., and Gallinella, G. (2012). Parvovirus B19 DNA CpG dinucleotide methylation and epigenetic regulation of viral expression. *PLoS ONE* 7:e33316. doi: 10.1371/journal.pone.0033316

Brass, C., Elliott, L. M., and Stevens, D. A. (1982). Academy rash. A probable epidemic of erythema infectiousum (‘fifth disease’). *JAMA* 248, 568–572. doi: 10.1001/jama.1982.03330500500303

Brown, K. E., Anderson, S. M., and Young, N. S. (1993). Erythrocyte P antigen: cellular receptor for B19 parvovirus. *Science* 262, 114–117. doi: 10.1126/science.821117

Bua, G., Manaresi, E., Bonvicini, F., and Gallinella, G. (2016). Parvovirus B19 replication and expression in differentiating erythroid progenitor cells. *PLoS ONE* 11:e0148547. doi: 10.1371/journal.pone.0148547

Caillet-Faquet, P., Draps, M. L. D., Giambattista, M., de Launoit, Y., and Laub, R. (2004). Hyaopex enables B19 erthrocytosis to yield abundant infectious progeny in a pluripotent erythroid cell line. *J. Virol. Methods* 121, 145–153. doi: 10.1016/j.jviromet.2004.06.010

Chen, A. Y., Zhang, E. Y., Guan, W., Cheng, F., Klebboeker, S., Yankee, T. M., et al. (2010b). The small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells. *Blood* 115, 1070–1080. doi: 10.1182/blood-2009-04-215756

Chorba, T., Coccia, P., Holman, R. C., Tattersall, P., Anderson, L. J., Sudman, J., et al. (1986). The role of parvovirus B19 in aplastic crisis and erythema infectiousum (fifth disease). *J. Infect. Dis.* 154, 383–393. doi: 10.1093/infdis/154.3.383

Ciccia, A., and Elledge, S. J. (2010). The DNA damage response: making it safe to play with knives. *Mol. Cell* 40, 179–204. doi: 10.1016/j.molcel.2010.09.016

Costas, Y., E., Field, A. M., Cant, B., and Widdows, D. (1975). Parvovirus-like particles in human sera. *Lancet* 1, 72–73. doi: 10.1016/S0140-6736(75)91074-0

Cotmore, S. F., Agbandje-McKenna, M., Chiorini, J. A., Mukha, D. V., Pintel, D. J., Qiu, J., et al. (2013). The family Paroviridae. *Arch. Virol.* 159, 1239–1247. doi: 10.1007/s00705-013-1914-1

Cotmore, S. F., McKie, V. C., Anderson, L. J., Astell, C. R., and Tattersall, P. (1986). Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. *J. Virol.* 60, 548–557.

Cotmore, S. F., and Tattersall, P. (2014). Paroviruses: small does not mean simple. *Ann. Rev. Virol.* 1, 517–537. doi: 10.1146/annurev-virology-031413-085444
Dai, C. H., Krantz, S. B., and Zsebo, K. M. (1991). Human burst-forming units-erythroid need direct interaction with stem cell factor for further development. Blood 78, 2493–2497.

Deleu, L., Pujol, A., Faissat, S., and Rommelaere, J. (1999). Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. J. Virol. 73, 3877–3885.

Doering, C., Beard, P., and Hirt, B. (1987). A transcriptional promoter of the human parvovirus B19 active in vitro and in vivo. Virology 157, 359–542. doi: 10.1016/0042-6822(87)90297-2

Dorsch, S., Kaufmann, B., Schäuble, U., Prohaska, E., Wolf, H., and Modrow, S. (2001). The VP1-unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J. Virol. 76, 2014–2018. doi: 10.1128/JVI.76.4.2014-2018.2002

Duchtecht, A., Tschöpe, C., Kaiser, H., Lamkemeyer, T., Tanaka, N., Aberle, S., Fan, M. M., Tamburic, L., Shippam-Brett, C., Zagrodney, D. B., and Astell, G., Grebien, F., Kerenyi, M. A., Kovacic, B., Kolbe, T., Becker, V., Dolznig, H., et al. (2011b). Internal polyadenylation of Ganaie and Qiu Recent Advances in Parvovirus B19.

Gigler, A., Dorsch, S., Hemauer, A., Williams, C., Kim, S., Young, N. S., et al. (1999). Guo, Y. M., Ishii, K., Hirokawa, M., Tagawa, H., Ohyagi, H., Michishita, Y., et al. (2010). CpG-ODN 2006 and human parvovirus B19 genome consensus sequences selectively inhibit growth and development of erythroid progenitor cells. Blood 115, 4569–4579. doi: 10.1182/blood-2009-08-239202

Harbison, C. E., Chiorini, J. A., and Parrish, C. R. (2008). The parvovirus capsid odyssey: from the cell surface to the nucleus. Trends Microbiol. 16, 208–214. doi: 10.1016/j.tim.2008.01.012

Heegaard, E. D., and Brown, K. E. (2002). Human parvovirus B19. Clin. Microbiol. Rev. 15, 485–505. doi: 10.1128/CMR.15.3.485-505.2002

Hoszu, E., and Sallai, A. (1997). “Human parvovirus B19 infection in a child suffering from chronic arthritis”. Orv. Hetil. 138, 611–613.

Kerr, J. R. (2000). Pathogenesis of human parvovirus B19 in rheumatic disease. Ann. Rheum. Dis. 59, 672–683. doi: 10.1136/ard.59.6.672

Koller, M. R., Bender, J. G., Miller, W. M., and Papoutsakis, E. T. (1992). Reduced oxygen tension increases hematopoesis in long-term culture of human stem and progenitor cells from cord blood and bone marrow. Exp. Hematol. 20, 264–270.

Koury, M. J., and Bondurant, M. C. (1992). The molecular mechanism of erythropoietin action. Eur. J. Biochem. 210, 649–663. doi: 10.1111/j.1432-1033.1992.tb13746.x

Kurtzman, G. I., Cohen, B. J., Field, A. M., Oseas, R., Blaes, R. M., and Young, N. S. (1989). Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J. Clin. Invest. 84, 1114–1123. doi: 10.1172/JCI114274

Leisi, R., Di Tommaso, C., Kempf, C., and Ros, C. (2016a). The receptor-binding domain in the VP1u region of parvovirus B19. Viruses 8:61. doi: 10.3390/v8030061

Leisi, R., Ruprecht, N., Kempf, C., and Ros, C. (2013). Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism. J. Virol. 87, 13161–13167. doi: 10.1128/JVI.02548-13

Leisi, R., Von Nordheim, M., Ros, C., and Kempf, C. (2016b). The VP1u receptor restricts parvovirus B19 uptake to permissive erythroid cells. Viruses 8:E265. doi: 10.3390/v80100265

Li, Y., Wang, J., Zhu, G., Zhang, X., Zhai, H., Zhang, W., et al. (2007). Detection of parvovirus B19 nucleic acids and expression of viral VP1/VP2 antigen in human colon carcinoma. Am. J. Gastroenterol. 102, 1489–1498. doi: 10.1111/j.1572-2241.2007.01240.x

Liu, J. M., Fujii, H., Green, S. W., Komatsu, N., Young, N. S., and Shimada, T. (1991). Indiscriminate activity from the B19 parvovirus p6 promoter in nonpermissive cells. Virology 182, 361–364. doi: 10.1016/0042-6822(91)90682-2

Liu, J. M., Green, S. W., Shimada, T., and Young, N. S. (1992). A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus. J. Virol. 66, 4686–4692.

Lodish, H. F., Ghafarsi, S., Socolovsky, M., Tong, W., and Zhang J. (2009). “Intracellular signaling by the erythropoietin receptor,” in Erythropoetins, Erythropoietic Factors and Erythropiesis, eds S. G. Elliott, M. A. Foote, and G. Molineux (Basel: Burkhauser Verlag), 155–174.

Longo, G., Luppi, M., Bertesi, M., Ferrara, L., Torelli, G., and Emilia, G. (1998). Still’s disease, severe thrombocytopenia, and acute hepatitis associated with acute parvovirus B19 infection. Clin. Infect. Dis. 26, 994–995. doi: 10.1086/376144

Luo, W., and Astell, C. R. (1993). A novel protein encoded by small RNAs of parvovirus B19 which facilitates viral DNA replication. J. Virol. 67c:02050-17. doi: 10.1128/JVI.67c.02050-17

Ganea and Qiu Recent Advances in Parvovirus B19.
Munakata, Y., Kato, I., Saito, T., Kodera, T., Ishii, K. K., and Sasaki, Momoeda, M., Wong, S., Kawase, M., Young, N. S., and Kajigaya, S. (1994b). A Miyagawa, E., Yoshida, T., Takahashi, H., Yamaguchi, K., Naga no, T., Kiriyama, Ganaie and Qiu. Recent Advances in Parvovirus B19

Morey, A. L., and Fleming, K. A. (1992). Immunophenotyping of fetal Parilla, B. V., Tamura, R. K., and Ginsberg, N. A. (1997). Association of

Ozawa, K., and Young, N. (1987). Characterization of capsid and noncapsid

Ozawa, K., Kurtzman, G., and Young, N. (1986). Replication of the B19

Oleksiewicz, M. B., and Alexandersen, S. (1997). S-phase-dependent cell cycle

Munshi, N. C., Zhou, S., Woody, M. J., Morgan, D. A., and Srivastava, A. (1993). Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J. Virol. 67, 562–566.

Nunoue, T., Okochi, K., Mortimer, P. M., and Cohen, B. J. (1985). Human parvovirus (B19) and erythema infectiosum. J. Pediatr. 107, 38–40. doi: 10.1016/S0022-3476(85)80610-7

Ogawa, M. (1993). Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844–2853.

Oleskiewicz, M. B., and Alexandersen, S. (1997). S-phase-dependent cell cycle disturbances caused by Aleutian mink disease parvovirus. J. Virol. 71, 1386–1396.

O’Sullivan, M. G., Anderson, D. C., Fikes, J. D., Bain, F. T., Carlsson, C. S., Green, S. W., et al. (1994). Identification of a novel simian parvovirus in cynomolgus monkeys with severe anemia. A paradigm of human B19 parvovirus infection. J. Clin. Invest. 93, 1571–1576. doi: 10.1122/JCI117136

Ozawa, K., Ayub, J., Hao, Y. S., Kurtzman, G., Shimada, T., and Young, N. (1987). Novel transcription map for the B19 (human) pathogenic parvovirus. J. Virol. 61, 2395–2406.

Ozawa, K., Ayub, J., and Young, N. (1988). Translational regulation of B19 parvovirus capsid protein production by multiple upstream AUG triplets. J. Biol. Chem. 263, 10922–10926.

Ozawa, K., Kurtzman, G., and Young, N. (1986). Replication of the B19 parvovirus in human bone marrow cell cultures. Science 233, 883–886. doi: 10.1126/science.3738514

Ozawa, K., and Young, N. (1987). Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J. Virol. 61, 2627–2630.

Papayannopoulou, T., Brice, M., and Blau, C. A. (1993). Kit ligand in synergy with interleukin-3 amplifies the erythroblastoid-independent, globin-synthesizing progeny of normal human burst-forming units-erythroid in suspension cultures: physiologic implications. Blood 81, 299–310.

Parilla, B. V., Tamura, R. K., and Ginsberg, N. A. (1997). Association of parvovirus infection with isolated fetal effusions. Am. J. Perinatol. 14, 357–358. doi: 10.1055/s-2007-994160

Parris, D. S., and Bates, R. C. (1976). Effect of bovine parvovirus replication on DNA, RNA, and protein synthesis in S phase cells. Virology 73, 72–78. doi: 10.1016/0042-6822(76)90061-1

Pascalini, G., Bonvicini, F., Foroni, L., Salì, N., and Gallinella, G. (2009). Placental endothelial cells can be productively infected by Parvovirus B19. J. Clin. Virol. 44, 33–38. doi: 10.1016/j.jcv.2008.10.008

Peng, C. Y., Graves, P. R., Ogg, S., Thoma, R. S., Byrnes, M. J., Wu, Z., et al. (1998). C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell Growth Differ. 9, 197–208.

Pillet, S., Annan, Z., Fichelson, S., and Morinet, F. (2003). Identification of a nonconventional motif necessary for the nuclear import of the human parvovirus B19 major capsid protein (VP2). Virology 306, 25–32. doi: 10.1006/viro.2002.0047-8

Polz, M. E., Adamson, L. A., Lau, X., Chang, M. N., Fowler, L. J., and Hobbs, J. A. (2013). Increased IL-6 detection in adult and pediatric lymphoid tissue harboring parvovirus B19. J. Clin. Virol. 57, 233–238. doi: 10.1016/j.jcv.2013.02.022

Poole, B. D., Karetyni, Y. V., and Naides, S. J. (2004). Parvovirus B19-induced apoptosis of hepatocytes. J. Virol. 78, 7775–7783. doi: 10.1128/JVI.78.14.7775-7783.2004

Poole, B. D., Zhou, J., Grote, A., Schaffnabauer, A., and Naides, S. J. (2006). Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein. J. Virol. 80, 4114–4121. doi: 10.1128/JVI.80.4114-4121.2006

Qiu, J., Soderlund-Venermo, M., and Young, N. S. (2017). Human Parvoviruses. Clin. Microbiol. Rev. 30, 43–113. doi: 10.1128/CMR.00040-16

Quattrocchi, S., Ruprecht, N., Bönsch, C., Bieli, S., Zürcher, C., Boller, K., et al. (2012). Characterization of the early steps of human parvovirus B19 infection. J. Virol. 86, 9274–9284. doi: 10.1128/JVI.01004-12

Raab, U., Bauer, B., Gigler, A., Beckenlehner, K., Wolf, H., and Modrow, S. (2001). Cellular transcription factors that interact with p6 promoter elements of parvovirus B19. J. Gen. Virol. 82, 1473–1480. doi: 10.1099/0022-1317-82-6-1473

Raab, U., Beckenlehner, K., Lowin, T., Niller, H. H., Doyle, S., and Modrow, S. (2002). NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3. Virology 293, 86–93. doi: 10.1006/viro.2001.1285

Rodriguez, M. E., Collins, J., Snow, J., Smith, J., Hays, T., and Klimpel, K. (2008). Hypoxia alters progression of the erythroid program. Exp. Hematol. 36, 17–27. doi: 10.1016/j.exphem.2007.08.014

Ros, C., Gerber, M., and Kempf, C. (2006). Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J. Virol. 80, 12017–12024. doi: 10.1128/JVI.01435-06

Sanchez, J. L., Wroblewski, E. K., Rivas, R., Estrella, V., and Heckeroth, A. R. (2018). Characterization of the early steps of human parvovirus B19 infection. J. Infect. Dis. 212, 1070–1081. doi: 10.1093/infdis/jiy178

Schwarz, T. F., Serke, S., Hottenträger, B., von Brunn, A., Baumann, H., Kirsch, A., et al. (1992). Replication of parvovirus B19 in hematopoietic progenitor cells generated in vitro from normal human peripheral blood. J. Virol. 66, 1273–1276.

Serke, S., Schwarz, T. F., Baumann, H., Kirsch, A., Hottenträger, B., Von Brunn, A., et al. (1991). Productive infection of in vitro generated haematopoietic progenitor cells from normal human adult peripheral blood with parvovirus B19: studies by morphology, immunocytochemistry, flow-cytometry and DNA-hybridization. Br. J. Haematol. 79, 6–13. doi: 10.1111/j.1365-2457.1991.tb07998.x

Shimomura, S., Komatsu, N., Frickhofen, N., Anderson, S., Kajigaya, S., and Young, N. S. (1992). First continuous propagation of B19 parvovirus in a cell line. Blood 79, 18–24.
